WT1 TCR T cell therapy - Cell Medica

Drug Profile

WT1 TCR T cell therapy - Cell Medica

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Imperial College of Science, Technology and Medicine; University College London
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 20 Jul 2017 Cell Therapy catapult initiates enrolment in a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) in United Kingdom (NCT02550535)
  • 20 Jun 2017 Catapult Therapy TCR has been acquired and merged into Cell Medica
  • 20 Jun 2017 Cell Medica plans a phase I/II trial of dominant WT1-TCR cell therapy for Solid tumours in late 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top